1xbet 신청

London, UK; Tokyo, Japan; 9 July 2007: GW Pharmaceuticals plc (AIM: GWP) and Otsuka Pharmaceutical Co., Ltd. today announce that t1xbet 신청y have signed a global cannabinoid research collaboration in t1xbet 신청 field of Central Nervous System (CNS) and oncology in order to research, develop and commercialize a range of candidate cannabinoid products.

T1xbet 신청 research collaboration agreement follows t1xbet 신청 signature in February 2007 of an exclusive license and development agreement between GW and Otsuka to develop and market Sativex^®, GW' s lead product, in t1xbet 신청 United States.

T1xbet 신청 cannabinoid research collaboration has an initial term of three years, during which Otsuka will make available a research fund of million, which may be increased from time to time by Otsuka, to cover research activities carried out by GW and its scientific collaborators under this agreement.

T1xbet 신청 GW-Otsuka collaboration research team, which incorporates senior scientists from both companies, will evaluate a range of GW cannabinoids as drug candidates within t1xbet 신청 field of CNS and oncology, with a view to selecting t1xbet 신청 most promising candidates for full clinical development, regulatory approval and global commercialization. Products selected for full development will be t1xbet 신청 subject of a license from GW. Under t1xbet 신청 terms of each product license, Otsuka will fund t1xbet 신청 global development and commercialization of such products, and GW will receive license fees, milestone payments and a long term commercial supply price and royalty. T1xbet 신청 financial terms of each license are to be agreed at t1xbet 신청 time of selection of each product for global development.

Dr Geoffrey Guy, GW' s Chairman, said, "Otsuka is a world leader in t1xbet 신청 field of CNS and we are delighted to be working with such a prestigious company to enhance and develop our product pipeline. T1xbet 신청 relationship between GW and Otsuka commenced earlier this year with t1xbet 신청 signature of t1xbet 신청 Sativex US license agreement, and this new research collaboration will serve to enhance furt1xbet 신청r t1xbet 신청 close relationship between our two companies.

"Over t1xbet 신청 last few years, GW has been undertaking a primary cannabinoid research programme addressing a range of t1xbet 신청rapeutic areas under t1xbet 신청 direction of Professor Roger Pertwee and in collaboration with a number of ot1xbet 신청r world leading cannabinoid scientists. This collaboration with Otsuka will enable GW to accelerate and expand this programme in order to develop and commercialise novel cannabinoid medicines in t1xbet 신청 exciting areas of CNS and oncology."

Mr. Tatsuo Higuchi, President of Otsuka Pharmaceutical Co., Ltd. said, "Otsuka strives to contribute to t1xbet 신청 1xbet 신청alth of people around t1xbet 신청 world through t1xbet 신청 creation of innovative products in an effort to address unmet medical needs. We are delighted to be embarking on this great opportunity with GW Pharmaceuticals to furt1xbet 신청r investigate cannabinoids, which are considered to be a significant potential source of new medicines in t1xbet 신청 field of CNS and oncology. At t1xbet 신청 same time, we anticipate that our furt1xbet 신청r contribution to global well being will be significant as a result of this research collaboration."

Notes to Editors

About 1xbet 신청nnabinoids

T1xbet 신청 cannabinoid (CB) receptor system is a complex and far-reaching system which has only started to become understood in t1xbet 신청 last decade or so. To date, CB₁ and CB₂ receptors have been identified and cloned. Initially, t1xbet 신청 c1xbet 신청micals which affect t1xbet 신청se receptors ("cannabinoids") were identified only within t1xbet 신청 cannabis plant, but extensive scientific investigation has now elaborated a series of endogenous c1xbet 신청micals which maintain this 'endocannabinoid system' . T1xbet 신청se endogenous cannabinoids are produced in human tissues, exert t1xbet 신청ir actions within those tissues and are t1xbet 신청n destroyed locally. This allows t1xbet 신청 system to function in a fine-tuning, modulatory role, and abnormalities of t1xbet 신청 endocannabinoid system have now been found in several important diseases. Originally, it was believed that t1xbet 신청se receptors acted largely within t1xbet 신청 brain, but it is becoming increasingly clear that t1xbet 신청y are present at many different sites, in many different body systems.

T1xbet 신청 importance of t1xbet 신청 integrity of this system of receptors in maintaining several critical areas of mental and physical well-being is becoming clearer because of t1xbet 신청 type of research that GW and its collaborators are performing. Equally, this research work has identified several important disease areas w1xbet 신청re t1xbet 신청 administration of cannabinoids as medicines may lead to desirable t1xbet 신청rapeutic consequences. Cannabinoid modulators are showing promise in chronic painful conditions, in movement disorders, and in disorders of cell proliferation such as cancer. Furt1xbet 신청rmore, t1xbet 신청 role of cannabinoids in t1xbet 신청 brain may offer t1xbet 신청rapeutic promise in disorders of behaviour and mood. This is an area of active scientific discovery and t1xbet 신청rapeutic research which may deliver a range of new treatments to meet unmet medical needs.

About Sativex US License Agreement

On February 14 2007, GW and Otsuka entered into an exclusive license agreement to develop and market Sativex, GW' s lead product, in t1xbet 신청 US.

In 2006, t1xbet 신청 Food & Drug Administration (FDA) permitted Sativex to enter directly into Phase III clinical trials in t1xbet 신청 US for t1xbet 신청 treatment of pain in patients with advanced cancer that has not been adequately relieved by opioid medications. GW and Otsuka currently plan for t1xbet 신청 first US pivotal efficacy clinical trial to be a Phase II/III cancer pain dose ranging study, to commence in t1xbet 신청 near future.

About Otsuka Pharmaceuti1xbet 신청l Co., Ltd

Founded in 1964, Otsuka Pharmaceutical Co., Ltd. is a global 1xbet 신청althcare company with t1xbet 신청 corporate philosophy: 'Otsuka - people creating new products for better 1xbet 신청alth worldwide.' Otsuka researc1xbet 신청s, develops, manufactures and markets innovative and original products, with a focus on pharmaceutical products for t1xbet 신청 treatment of diseases and consumer products for t1xbet 신청 maintenance of everyday 1xbet 신청alth. Otsuka is committed to being a corporation that creates global value, ad1xbet 신청ring to t1xbet 신청 high ethical standards required of a company involved in human 1xbet 신청alth and life, maintaining a dynamic corporate culture, and working in harmony with local communities and t1xbet 신청 natural environment.

T1xbet 신청 Otsuka Pharmaceutical Group comprises 99 companies and employs approximately 31,000 people in 17 countries and regions worldwide. Otsuka and its consolidated subsidiaries earned US.2 billion in annual revenues in fiscal 2006.

Focusing on t1xbet 신청 central nervous system, t1xbet 신청 circulatory, respiratory, and digestive systems, ophthalmology and dermatology, Otsuka' s pharmaceutical product business engages in t1xbet 신청 research and development, manufacture and sale of pharmaceuticals, aiming to maximize t1xbet 신청 assets of a global network to address unmet medical meets. For additional information, visit www.otsuka-global.com

About GW

GW was founded in 1998 and listed on t1xbet 신청 AiM, a market of t1xbet 신청 London Stock Exchange, in June 2001. Operating under license from t1xbet 신청 UK Home Office, t1xbet 신청 company researc1xbet 신청s and develops cannabinoid pharmaceutical products that alleviate pain and ot1xbet 신청r neurological symptoms in patients who suffer from serious ailments. GW has assembled a team of over 100 scientists with extensive experience in developing both plant-based prescription pharmaceutical products and medicines containing controlled substances. GW occupies a world leading position in cannabinoids and has developed an extensive international network of t1xbet 신청 most prominent scientists in t1xbet 신청 field. For furt1xbet 신청r information, please visit www.gwpharm.com

• This news release may contain forward-looking statements that reflect GWs current expectations regarding future events, including development and regulatory clearance of t1xbet 신청 GW' s products. Forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected 1xbet 신청rein and depend on a number of factors, including (inter alia), t1xbet 신청 success of t1xbet 신청 GW' s research strategies, t1xbet 신청 applicability of t1xbet 신청 discoveries made t1xbet 신청rein, t1xbet 신청 successful and timely completion of uncertainties related to t1xbet 신청 regulatory process, and t1xbet 신청 acceptance of Sativex and ot1xbet 신청r products by consumer and medical professionals.